The Neurobiology of the Substantia Nigra Pars Compacta: from Motor to Sleep Regulation

被引:25
作者
Lima, Marcelo M. S. [1 ]
Reksidler, Angela B. B. [2 ]
Vital, Maria A. B. F. [2 ]
机构
[1] Univ Fed Santa Catarina, Dept Farmacol, Ctr Ciencias Biol, BR-88049900 Florianopolis, SC, Brazil
[2] Univ Fed Parana, Dept Farmacol, BR-80060000 Curitiba, Parana, Brazil
来源
JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT | 2009年 / 73期
关键词
6-OHDA; Motor; MPTP; Sleep; Substantia nigra pars compacta; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; 6-HYDROXYDOPAMINE INDUCED DEGENERATION; INDUCED DOPAMINERGIC NEUROTOXICITY; MPTP-MOUSE MODEL; PARKINSONS-DISEASE; PARADOXICAL SLEEP; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; RAT-BRAIN; L-DOPA; NEURONS;
D O I
10.1007/978-3-211-92660-4_11
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Clinical characteristics of Parkinson's disease (PD) are the result of the degeneration of the neurons of the substantia nigra pars compacta (SNpc). Several mechanisms are implicated in the degeneration of nigrostriatal neurons such as oxidative stress, mitochondrial dysfunction, protein misfolding, disturbances of dopamine (DA) metabolism and transport, neuroinflammation, and necrosis/apoptosis. The literature widely explores the neurotoxic models elicited by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA). Because of the models, it is known that basal ganglia, particularly substantia nigra, have been related to a diversity of functions, from motor to sleep regulation. Nevertheless, a current debate concerning the role of DA on the sleep-wake cycle is in progress. In summary, it is suggested that the dopaminergic system is implicated in the physiology of sleep, with particular regard to the influence of the SNpc neurons. The understanding of the functioning and connectivity of the SNpc neurons has become fundamental to discovering the neurobiology of these neurons.
引用
收藏
页码:135 / 145
页数:11
相关论文
共 104 条
  • [1] Andrade L A, 1987, Arq Neuropsiquiatr, V45, P217
  • [2] Arnulf I, 2006, J NEURAL TRANSM-SUPP, P357
  • [3] Parkinson's disease and sleepiness - An integral part of PD
    Arnulf, I
    Konofal, E
    Merino-Andreu, M
    Houeto, JL
    Mesnage, V
    Welter, ML
    Lacomblez, L
    Golmard, JL
    Derenne, JP
    Agid, Y
    [J]. NEUROLOGY, 2002, 58 (07) : 1019 - 1024
  • [4] Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation
    Asanuma, Masato
    Miyazaki, Ikuko
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2006, 6 (09) : 1313 - 1325
  • [5] BARBEAU A, 1961, CMONOAMINES SYSTEME, P247
  • [6] Neurodegenerative diseases and oxidative stress
    Barnham, KJ
    Masters, CL
    Bush, AI
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (03) : 205 - 214
  • [7] Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease
    Berman, SB
    Hastings, TG
    [J]. JOURNAL OF NEUROCHEMISTRY, 1999, 73 (03) : 1127 - 1137
  • [8] BIRKMAYER W, 1961, KLIN WOCHENSCHR, V73, P787
  • [9] Toxin-induced models of Parkinson's disease
    Bové J.
    Prou D.
    Perier C.
    Przedborski S.
    [J]. NeuroRX, 2005, 2 (3): : 484 - 494
  • [10] Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats
    Braga, R
    Kouzmine, I
    Canteras, NS
    Da Cunha, C
    [J]. EXPERIMENTAL NEUROLOGY, 2005, 192 (01) : 134 - 141